Cayman YKL-05-099

YKL-05-099 is an inhibitor of salt-inducible kinase 2 (SIK2; IC₅₀ = 0.04 µM for the human enzyme).¹ It is selective for SIK2 over a panel of 141 kinases at 1 µM but also inhibits 14 other kinases, including SIK3, Ephrin receptors, and Src. YKL-05-099 increases IL-10 production in zymosan A-induced isolated mouse bone marrow-derived dendritic cells (BMDCs; EC₅₀ = 0.46 µM), as well as decreases TNF-α, IL-6, and IL-12p40 levels and increases IL-1β levels in LPS-stimulated BMDCs when used at a concentration of 1 µM. It inhibits the proliferation of MOLM-13 leukemia cells (IC₅₀ = 0.24 µM).² In vivo, YKL-05-099 (10 µmol/kg) increases the bone formation rate and number of femoral osteoblasts and decreases the number of femoral osteoclasts in mice.³

WARNING This product is not for human or veterinary use.